Oral vitamin C × serum urate: a small average reduction differs from gout treatment

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionWhich urate question is addressed?Required	The outcome is reduced serum urate in adults. Serum urate in mg/dL or mmol/L and gout attacks, first onset or recurrence are different questions. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Direct comparison of oral single-ingredient C and serum urate in adults	Material needed: Original population, comparator and blood-test endpoint/time tables are needed. Gout prevention, cure or replacement of standard medication is not added. This records needed materials; no new research was executed.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionAre tablets/capsules and C-added drinks distinguished?Required	The formulation distinguishes tablets/capsules from the 2026 sugar-matched C-added drink. Naturally occurring food C, combinations and IV use are not automatically included. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Products/ingredients of ascorbic acid tablets/capsules and sugar-matched added-C drinks	Material needed: Original product, salt, added ingredients/sugars, manufacturing, excipients and single-agent conditions are needed. Formulation equivalence is not certified. This records needed materials; no new research was executed.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionAre 500 mg and nominal 600/measured 592±12 mg retained?Required	Doses are main-trial 500 mg/day and the 2026 single-agent drink’s nominal 600 mg (measured 592±12 mg). Original units/± are retained without deriving conversions or recommendations. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Trial-specific dose, measured content, frequency and exposure	Material needed: Original measurement, dispersion definition, ingredients, administration/adherence and trial-specific dose linkage are needed. This records needed materials; no new research was executed.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionAre 2 months, 8 weeks and 2 weeks retained separately?Required	The duration distinguishes 2 months and 8 weeks from the 2026 trial’s 2 weeks. R01 bibliography records 184 participants over 2 months. Results are not relabeled as one duration. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Original-trial exposure, measurement and follow-up end points	Material needed: Each report’s original schedule, actual dosing, post-stopping course and period/time linkage are needed. This records needed materials; no new research was executed.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionAre non-gout, healthy high-urate and established-gout populations distinguished?Required	The population separates adults without gout or healthy high-urate adults from established gout. The existing counterview retains differences in baseline urate, deficiency, medication and applicability to gout. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Population-specific baseline urate, diagnosis, deficiency and urate medication	Material needed: Original diagnosis, baseline tests, medication/deficiency, eligibility/exclusions and group tables are needed. A pooled mean is not used as every population’s value. This records needed materials; no new research was executed.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionAre placebo, drinks and allopurinol retained as different contrasts?Required	The comparator separates placebo/sugar-matched drinks from direct allopurinol initiation or titration comparisons. An active-drug contrast is not relabeled as a placebo test of 0 effect. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	R01 placebo, R02 active-drug and R03 sugar-matched drink conditions	Material needed: Original report/stratum-specific group conditions, drug initiation/titration, matched drinks and common care are needed. This records needed materials; no new research was executed.
7	Unverified	Full text not readStored summary read	N07 · Evidence conditionCan diet, urate medication, coadministration and adherence be separated?Required	The account retains applicability differences involving baseline urate medication, deficiency and sugary drinks. Detailed actual group-specific diet, medication and adherence remain unverified here. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Baseline medication, treatment changes, diet/drinks and actual exposure	Material needed: Original maintained/changed medication, diet, common care, adherence and discontinuation records are needed. An isolated C effect is not established. This records needed materials; no new research was executed.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionWhat are the R01 sample of 184 and group analysis denominators?Required	R01 records 184 participants; group allocation and final analysis sample sizes remain unverified. Group counts, completers and attrition are not newly created. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Huang trial allocation, analysis, completion and urate denominators	Material needed: Original group flow, analysis/completion, missing endpoints and exclusion/missingness rules are needed. This records needed materials; no new research was executed.
9	Partly verified	Full text not readStored summary read	N09 · Evidence conditionWhat are R01 group-specific changes and CIs?Required	The original result is C change −0.5 mg/dL (95% CI −0.6, −0.3), placebo +0.09 (−0.05, 0.2), between-group P<.0001. Group-change CIs are not transferred into a between-group difference CI. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Separate C/placebo change intervals and the between-group test	Material needed: Original change/variance, groups/time points, denominators and adjustment/test tables are needed. This records needed materials; no new research was executed.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionIs the existing −0.59 calculation distinguished from its missing CI?Required	The stored change difference −0.59 mg/dL is a calculation without its own 95% CI. It is not a new calculation or certification of an adjusted/precise effect in this work. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Historical simple change difference and original between-group estimate/CI	Material needed: Original between-group estimates, variance, CIs and model are needed. Group-specific CIs are not reused or reverse-calculated. This records needed materials; no new research was executed.
11	Partly verified	Full text not readStored summary read	N11 · Evidence conditionAre R01 allocation, blinding and prior urate hierarchy known?Required	R01 is a double-blind placebo RCT, but prior registration/SAP remain unverified. A design label does not certify every method or prespecification. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Sequence, concealment, blinding, registration/SAP and primary endpoint	Material needed: Original methods, registration, plans and all endpoints/time points are needed. No formal RoB2/GRADE is produced. This records needed materials; no new research was executed.
12	Partly verified	Full text not readStored summary read	N12 · Evidence conditionAre the two R02 allopurinol strata kept distinct from treatment arms?Required	R02 records 40 participants: 20 existing allopurinol users and 20 nonusers, with allocation within each stratum. These 20/20 are not relabeled as C-arm/active-control counts. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Allocation/denominators within strata of 20 prior users and 20 nonusers	Material needed: Stratum-specific drug initiation/titration, group allocation/analysis, baseline urate and flow tables are needed. Participants are not summed. This records needed materials; no new research was executed.
13	Partly verified	Full text not readStored summary read	N13 · Evidence conditionWhat are the urate reductions in the R02 active comparison?Required	R02 records reductions of 0.23 versus 1.9 mg/dL, P<.001, with the exact adjusted between-group CI unverified. The comparison shows a smaller response than allopurinol, not no C effect versus placebo. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Contrast, P value and adjusted CI for reductions of 0.23 versus 1.9 mg/dL	Material needed: Original stratum/group, variance, model, CI and time/denominator result tables are needed. No new difference, 0 effect or flare-prevention estimate is created. This records needed materials; no new research was executed.
14	Partly verified	Full text not readStored summary read	N14 · Evidence conditionAre the R02 open-label design and registration citation distinct from actual plans?Required	The design is an open-label randomized pilot with an active comparison. ACTRN12610000545066 is reported in the paper; official registration details remain unverified. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Open-label pilot methods and official ACTRN history	Material needed: Original methods, within-stratum allocation, registration/changes and protocol/SAP are needed. A registration identifier does not establish prespecification or reading. This records needed materials; no new research was executed.
15	Partly verified	Full text not readStored summary read	N15 · Evidence conditionIs the 2026 two-period/group design preserved?Required	R03 uses randomized drink comparisons with two study groups and two periods; not everyone received all four drinks. It is not relabeled as a universal 4-drink crossover. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	HesperidrinC groups/periods, drinks and crossover/allocation conditions	Material needed: Original allocation/sequence, periods, drink conditions, washout, assessments/denominators and plans are needed. This records needed materials; no new research was executed.
16	Partly verified	Full text not readStored summary read	N16 · Evidence conditionAre 43 assigned, 40 analysed and 20 each for C/control distinguished?Required	R03 records 43 assigned→40 analysed; 20 each for C and control drinks. Additional combination drinks, periods or people are not added and attrition is not calculated. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	R03 allocation, analysis and single-agent drink contrast denominators	Material needed: Original group/period flow, endpoint denominators, missingness/exclusions and same-participant linkage are needed. This records needed materials; no new research was executed.
17	Partly verified	Full text not readStored summary read	N17 · Evidence conditionAre time-specific R03 model mean±SE values preserved?Required	R03 records C 6.02±.20→5.54±.20 (week 1)→5.71±.20 (week 2); control 5.86±.20→5.76±.20→5.86±.20, as model mean±SE. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	C/control baseline, week 1 and week 2 model means/SE	Material needed: Original units, model, adjustment, time/group, denominators and all contrasts are needed. SE is not relabeled as SD/CI and differences are not calculated. This records needed materials; no new research was executed.
18	Partly verified	Full text not readStored summary read	N18 · Evidence conditionAre within-C P values distinguished from undetected between-drink differences?Required	R03 retains within-C week 1 P<.01 alongside no detected time-specific between-group difference in the original account. It is not counted as positive between-group replication equivalent to the early RCT. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Within-group week 1 test and time-specific control contrasts	Material needed: Original between-group estimates/CIs, multiplicity, model and all time points are needed. Within-group significance is not converted into a placebo effect, equivalence or precise null effect. This records needed materials; no new research was executed.
19	Partly verified	Full text not readStored summary read	N19 · Evidence conditionAre C+hesperidin and observational diet excluded from single-agent effects?Required	The existing explanation excludes C+hesperidin and observational diet from single-agent confirmation. A combination in the paper title is not copied into an isolated effect. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Original contrasts for single-agent drinks versus combinations/natural diet	Material needed: Original drink ingredients, allocation/periods, single-agent contrasts and distinction from combination/observational material are needed. This records needed materials; no new research was executed.
20	Partly verified	Full text not readStored summary read	N20 · Evidence conditionAre R03 official registration hierarchy and the paper-reported number distinguished?Required	The registration/citation record retains the paper-reported NCT04316390 identifier, while official history, primary hierarchy and time-point correspondence remain unverified. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Official NCT04316390 change history and primary endpoints/time points	Material needed: Original registration, changes, plans and analysis tables are needed. Current registration reading, compliance or prespecification is not certified. This records needed materials; no new research was executed.
21	Partly verified	Full text not readStored summary read	N21 · Evidence conditionIs the pooled report of 13 RCTs kept distinct from a new primary trial?Required	Bibliography-only R04 retains an average −0.35 mg/dL across 13 RCTs with substantial heterogeneity. Included-trial counts come from the original summary and are not new certification of unique trials or independent replication. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Juraschek review included/shared trials, extraction and heterogeneity	Material needed: Original inclusion/extraction tables, model, CIs, denominators and shared-trial/report links are needed. Review and primary-trial participants are not summed. This records needed materials; no new research was executed.
22	Partly verified	Full text not readStored summary read	N22 · Evidence conditionAre differences by disease, baseline status and medication retained?Required	The original rationale retains mixed gout/high-urate results, while the counterview retains baseline and medication applicability limits. Findings are not simply merged as identical replication of one question. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Directness for gout/non-gout, high urate, deficiency and medication	Material needed: Original disease/baseline, formulation, duration, medication-specific effects/denominators and prespecified subgroups/interactions are needed. This records needed materials; no new research was executed.
23	Partly verified	Full text not readStored summary read	N23 · Evidence conditionAre urate units, measurement and analysis sets distinguished?Required	The primary endpoint is serum urate in mg/dL or mmol/L. Original units are not converted and serum concentrations are not relabeled as flare outcomes. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	mg/dL, mmol/L, baseline/change values and measurement/adjustment	Material needed: Original assay, units, blood sampling/time points, baseline adjustment, variance and estimand are needed. This records needed materials; no new research was executed.
24	Unverified	Full text not readStored summary read	N24 · Evidence conditionWhat is the original impact of missingness, attrition and selective reporting?Required	R01 unverified final group sample sizes, R02 within-stratum allocation and R03 allocation/analysis records are distinguished. Detailed missingness/exclusion rules remain unverified here. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Group/stratum/period missingness, discontinuation, denominators and handling	Material needed: Flow, attrition/exclusions, missing-data handling, all planned time points and sensitivity material are needed. This records needed materials; no new research was executed.
25	Partly verified	Full text not readStored summary read	N25 · Evidence conditionAre first-onset gout, recurrence, cure and drug replacement kept separate?Supplementary	The existing explanation treats clinical gout as a separate question. Urate reduction or active-drug comparisons are not proof of first onset, recurrence, cure or drug replacement. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Direct comparison of serum urate and clinical gout events	Material needed: Direct tests of attacks, first onset, recurrence or drug replacement are separately needed. Other verdicts/research are not newly accessed here. This records needed materials; no new research was executed.
26	Partly verified	Full text not readStored summary read	N26 · Evidence conditionAre four company-involvement pathways and the three trials retained separately?Required	R01 funding/manufacturer involvement is unverified; R02 records HRC New Zealand support with product/employee details unverified; R03 retains no external grant plus Döhler/Eckes-Granini/Ferrer in-kind support/I1. No grant is not relabeled as no company involvement. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Funding, in-kind/product support, employee authors and COI	Material needed: Original funding, in-kind/products, affiliations, COI and report-specific linkage are needed. Overall I2 and specific R03 I1 records are not replaced or rescored. This records needed materials; no new research was executed.
27	Partly verified	Full text not readStored summary read	N27 · Evidence conditionAre 4 reports distinguished from unique trials and participants?Required	The 3 trial summaries and 4 citations represent primary-material/review units. Original I2/R0 records are retained; independent replication or final unique trial/participant totals are not certified here. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Research families/shared samples of three original trials/comparisons and a review	Material needed: Registration, institutions/timing, teams, products and included/additional-report/same-sample links are needed. Final totals are null. This records needed materials; no new research was executed.
28	Partly verified	Full text not readStored summary read	N28 · Evidence conditionAre harm collection, events and discontinuation known?Supplementary	The original safety account retains high-dose gastrointestinal caution and limited event counts. Actual events, collection and causality are not newly established. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Definition, collection and events/discontinuation for diarrhoea/gastrointestinal harms	Material needed: Original harm methods, severity, events/discontinuation, missingness and comparator records are needed. This records needed materials; no new research was executed.
29	Unverified	Full text not readStored summary read	N29 · Evidence conditionWhat are the safety denominators, exposure and comparators?Supplementary	The 184, 40 and 43 assigned/40 analysed do not certify safety denominators. Different periods, medication or drinks are not combined as identical harm exposure. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Group/stratum/period actual treatment, safety sets and exposure/events	Material needed: Group-specific safety denominators, exposure/discontinuation, events and comparator/stratum/period linkage are needed. Incidence and totals are not calculated. This records needed materials; no new research was executed.
30	Partly verified	Full text not readStored summary read	N30 · Evidence conditionWhat is known about kidney disease, stones, iron overload, coadministration and long-term harms?Supplementary	The product account’s caution for stone predisposition, kidney disease and iron overload is retained. Urate results are not converted into certification of kidney/stone or long-term safety. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Vulnerable groups, alternative causes/medication and rare/long-term/independent harms	Material needed: Vulnerable populations, coadministration, event timing/alternative causes, independent reports, longer exposure and denominators are needed. No new harm search or judgment is performed. This records needed materials; no new research was executed.
31	Partly verified	Full text not readStored summary read	N31 · Evidence conditionAre historical HTML/PDF/abstract checks distinguished from current unread material?Required	Citations retain historical abstract/institutional bibliography checks and 2026 HTML/tables/methods/PDF-text checks with a PDF-screenshot cache failure. These are historical records, not current external reading or access testing. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Original access record, stored summary and external abstracts/full text/registration/plans	Material needed: External material remains unread now. A past cache failure is not converted into current paper inaccessibility, and past checks are not promoted into newly completed QA. This records needed materials; no new research was executed.
32	Partly verified	Full text not readStored summary read	N32 · Evidence conditionAre Korean/English text, empty corrections and prior calculation records preserved?Supplementary	Korean/English text, empty correction/subclaim arrays and the original −0.59 calculation label are retained. No new calculation, correction or completed English clinical review is created. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Complete originals, empty correction/subclaim records and prior calculation	Material needed: After content review, new material, corrections or verdict changes are recorded as separate events. This records needed materials; no new research was executed.
33	Partly verified	Full text not readStored summary read	N33 · Evidence conditionAre original C54, axes and evidence date distinct from production?Required	C/54/caution, original assessment axes and the existing evidence date 2026-09-07 are retained. Original independence/pooled-signal wording is historical, not a new grade or certification in this work. R01 R02 R03 R04	This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.	Original C54, caution, assessment axes and evidence date	Material needed: New material, condition revisions and verdict changes are separate events after content review. The original date is not used as a current search or external reading date. This records needed materials; no new research was executed.

No items match your search or filter.

33 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-09-07
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: Adults without gout and healthy adults with high urate are distinguished from established gout. Details of baseline urate, deficiency, urate-lowering medication and group composition remain unverified.
Ingredient, formulation and route: Oral single-ingredient ascorbic acid tablets/capsules are distinguished from the 2026 C-added sugar-matched drink. Naturally occurring food C, combinations, intravenous use and hesperidin coadministration are not automatically included.
Dose: Main-trial 500 mg/day and the 2026 single-agent drink’s nominal 600 mg and measured 592±12 mg are retained. The measured dispersion definition and actual exposure/adherence remain unverified.
Comparator: Placebo and the sugar-matched drink are distinguished from active comparisons involving allopurinol initiation or titration. Strata defined by prior use are not relabeled as C and active-drug allocation arms.
Measured outcome: This concerns serum urate in mg/dL or mmol/L. A concentration change does not directly establish first-onset gout, attacks, recurrence, cure or replacement of standard medication. Units are not newly converted.
Duration: 2 months and 8 weeks are distinguished from the 2026 trial’s 2 weeks. Week 1 and week 2 visits, study periods and actual dosing/post-stopping follow-up are not combined as one duration.
Questions outside this scope: Existing C54, caution, B/S/R0/I2/E+/B2/C0, disabled indicators and empty values are preserved. Historical independent-comparison wording and pooled signals do not establish completed clinical content review in this work.; The existing −0.59 mg/dL is a calculated simple change difference without its own 95% CI. CIs for each group’s change are not used as a between-group CI, and no new difference or interval is calculated.; The 20 existing allopurinol users and 20 nonusers define strata for allocation within each stratum. They are not relabeled as 20 in the C arm and 20 in the active-drug arm.; The 2026 single-agent C drink’s within-group week 1 P<.01 and absence of detected time-specific between-group differences are retained together. Model mean±SE is not relabeled as SD or CI, and the design is not relabeled as every participant receiving all four drinks.; The review’s average −0.35 mg/dL across 13 RCTs and substantial heterogeneity are retained without adding primary-trial and review participants. Serum urate is not extended into proof of preventing or curing gout or replacing standard treatment.; Existing caution concerning gastrointestinal effects of high oral doses and stone risk, kidney disease and iron overload is retained. Unverified report-specific harm collection, denominators and long-term details do not establish absence of harm or individual dosing instructions.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · Huang et al. 2005

PubMed

Material type: Stored summary of a double-blind placebo trial
Materials actually read: Existing stored review summary read; external material unread
Findings recorded in the stored summary: C change −0.5 mg/dL (95% CI −0.6, −0.3), placebo +0.09 (−0.05, 0.2), between-group P<.0001. The existing net change −0.59 mg/dL is a calculation without its own 95% CI.
Record level: This concerns 184 participants over 2 months. Group allocation and final analysis denominators remain unverified. CIs for group-specific changes are not transferred into the between-group difference or a flare outcome.
Study overlap and independent replication: The 4 stored reports comprise 3 trial reports involving direct placebo, active allopurinol and single-agent C drink comparisons plus 1 pooled-review bibliography. Groups, strata, periods, disease and included/shared samples are distinguished; unique trial/participant totals and independent replication remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Preserved copy of the complete existing review summary	Stored summary	Summary read	PMID15934094 · DOI10.1002/art.21105 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
External abstract	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID15934094 · DOI10.1002/art.21105 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
External full text	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID15934094 · DOI10.1002/art.21105 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
Registration material	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID15934094 · DOI10.1002/art.21105 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
Protocol and analysis plan	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID15934094 · DOI10.1002/art.21105 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.

R02 · Stamp et al. 2013

PubMed

Material type: Open-label randomized active-drug comparison pilot in established gout
Materials actually read: Existing stored review summary read; external material unread
Findings recorded in the stored summary: Urate reductions of 0.23 versus 1.9 mg/dL, P<.001. The exact adjusted between-group 95% CI remains unverified. This compares a smaller response with allopurinol; it is not a placebo test of no C effect.
Record level: Among 40 participants, allocation occurred within strata of 20 existing allopurinol users and 20 nonusers. ACTRN12610000545066 is a paper-reported identifier; official details, change history and plan compliance remain unverified.
Study overlap and independent replication: The 4 stored reports comprise 3 trial reports involving direct placebo, active allopurinol and single-agent C drink comparisons plus 1 pooled-review bibliography. Groups, strata, periods, disease and included/shared samples are distinguished; unique trial/participant totals and independent replication remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Preserved copy of the complete existing review summary	Stored summary	Summary read	PMID23681955 · DOI10.1002/art.37925 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
External abstract	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID23681955 · DOI10.1002/art.37925 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
External full text	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID23681955 · DOI10.1002/art.37925 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
Registration material	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID23681955 · DOI10.1002/art.37925 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
Protocol and analysis plan	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID23681955 · DOI10.1002/art.37925 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.

R03 · Enderle et al. 2026

Official source

Material type: Randomized drink comparison with two study groups and two periods
Materials actually read: Existing stored review summary read; external material unread
Findings recorded in the stored summary: Model mean±SE: C 6.02±.20→5.54±.20 (week 1)→5.71±.20 (week 2), control 5.86±.20→5.76±.20→5.86±.20. Within-C week 1 P<.01; the original account states no detected time-specific between-group difference.
Record level: The 43 assigned, 40 analysed and 20 each for C and control drinks are distinguished. Not all participants received all four drinks; C+hesperidin is excluded from single-agent confirmation. Official NCT04316390 history and hierarchy remain unverified.
Study overlap and independent replication: The 4 stored reports comprise 3 trial reports involving direct placebo, active allopurinol and single-agent C drink comparisons plus 1 pooled-review bibliography. Groups, strata, periods, disease and included/shared samples are distinguished; unique trial/participant totals and independent replication remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Preserved copy of the complete existing review summary	Stored summary	Summary read	PMID41739218 · DOI10.1007/s00394-026-03905-z is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
External abstract	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID41739218 · DOI10.1007/s00394-026-03905-z is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
External full text	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID41739218 · DOI10.1007/s00394-026-03905-z is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
Registration material	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID41739218 · DOI10.1007/s00394-026-03905-z is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
Protocol and analysis plan	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID41739218 · DOI10.1007/s00394-026-03905-z is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.

R04 · Juraschek et al. 2011

PubMed

Material type: Bibliography and summary of a pooled review of randomized trials
Materials actually read: Existing stored review summary read; external material unread
Findings recorded in the stored summary: The existing citation records an average −0.35 mg/dL across 13 RCTs and substantial heterogeneity.
Record level: PMCID PMC3169708 is retained in the original bibliography. Inclusion, extraction, shared trials, denominators and exact CIs remain unverified. The review is not added as a new primary trial and participants are not summed.
Study overlap and independent replication: The 4 stored reports comprise 3 trial reports involving direct placebo, active allopurinol and single-agent C drink comparisons plus 1 pooled-review bibliography. Groups, strata, periods, disease and included/shared samples are distinguished; unique trial/participant totals and independent replication remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Preserved copy of the complete existing review summary	Stored summary	Summary read	PMID21671418 · DOI10.1002/acr.20519 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
External abstract	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID21671418 · DOI10.1002/acr.20519 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
External full text	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID21671418 · DOI10.1002/acr.20519 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
Registration material	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID21671418 · DOI10.1002/acr.20519 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.
Protocol and analysis plan	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	PMID21671418 · DOI10.1002/acr.20519 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date.

Report counts versus independent study counts

The 4 stored reports comprise 3 trial reports involving direct placebo, active allopurinol and single-agent C drink comparisons plus 1 pooled-review bibliography. Groups, strata, periods, disease and included/shared samples are distinguished; unique trial/participant totals and independent replication remain unverified.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which urate question is addressed?

Required materials and conditions: Direct comparison of oral single-ingredient C and serum urate in adults
Conditions for verification: Original records on Direct comparison of oral single-ingredient C and serum urate in adults must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Direct comparison of oral single-ingredient C and serum urate in adults is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N02 · Are tablets/capsules and C-added drinks distinguished?

Required materials and conditions: Products/ingredients of ascorbic acid tablets/capsules and sugar-matched added-C drinks
Conditions for verification: Original records on Products/ingredients of ascorbic acid tablets/capsules and sugar-matched added-C drinks must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Products/ingredients of ascorbic acid tablets/capsules and sugar-matched added-C drinks is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N03 · Are 500 mg and nominal 600/measured 592±12 mg retained?

Required materials and conditions: Trial-specific dose, measured content, frequency and exposure
Conditions for verification: Original records on Trial-specific dose, measured content, frequency and exposure must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Trial-specific dose, measured content, frequency and exposure is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N04 · Are 2 months, 8 weeks and 2 weeks retained separately?

Required materials and conditions: Original-trial exposure, measurement and follow-up end points
Conditions for verification: Original records on Original-trial exposure, measurement and follow-up end points must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Original-trial exposure, measurement and follow-up end points is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N05 · Are non-gout, healthy high-urate and established-gout populations distinguished?

Required materials and conditions: Population-specific baseline urate, diagnosis, deficiency and urate medication
Conditions for verification: Original records on Population-specific baseline urate, diagnosis, deficiency and urate medication must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Population-specific baseline urate, diagnosis, deficiency and urate medication is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N06 · Are placebo, drinks and allopurinol retained as different contrasts?

Required materials and conditions: R01 placebo, R02 active-drug and R03 sugar-matched drink conditions
Conditions for verification: Original records on R01 placebo, R02 active-drug and R03 sugar-matched drink conditions must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on R01 placebo, R02 active-drug and R03 sugar-matched drink conditions is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N07 · Can diet, urate medication, coadministration and adherence be separated?

Required materials and conditions: Baseline medication, treatment changes, diet/drinks and actual exposure
Conditions for verification: Original records on Baseline medication, treatment changes, diet/drinks and actual exposure must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Baseline medication, treatment changes, diet/drinks and actual exposure is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N08 · What are the R01 sample of 184 and group analysis denominators?

Required materials and conditions: Huang trial allocation, analysis, completion and urate denominators
Conditions for verification: Original records on Huang trial allocation, analysis, completion and urate denominators must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Huang trial allocation, analysis, completion and urate denominators is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N09 · What are R01 group-specific changes and CIs?

Required materials and conditions: Separate C/placebo change intervals and the between-group test
Conditions for verification: Original records on Separate C/placebo change intervals and the between-group test must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Separate C/placebo change intervals and the between-group test is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N10 · Is the existing −0.59 calculation distinguished from its missing CI?

Required materials and conditions: Historical simple change difference and original between-group estimate/CI
Conditions for verification: Original records on Historical simple change difference and original between-group estimate/CI must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Historical simple change difference and original between-group estimate/CI is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N11 · Are R01 allocation, blinding and prior urate hierarchy known?

Required materials and conditions: Sequence, concealment, blinding, registration/SAP and primary endpoint
Conditions for verification: Original records on Sequence, concealment, blinding, registration/SAP and primary endpoint must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Sequence, concealment, blinding, registration/SAP and primary endpoint is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N12 · Are the two R02 allopurinol strata kept distinct from treatment arms?

Required materials and conditions: Allocation/denominators within strata of 20 prior users and 20 nonusers
Conditions for verification: Original records on Allocation/denominators within strata of 20 prior users and 20 nonusers must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Allocation/denominators within strata of 20 prior users and 20 nonusers is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N13 · What are the urate reductions in the R02 active comparison?

Required materials and conditions: Contrast, P value and adjusted CI for reductions of 0.23 versus 1.9 mg/dL
Conditions for verification: Original records on Contrast, P value and adjusted CI for reductions of 0.23 versus 1.9 mg/dL must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Contrast, P value and adjusted CI for reductions of 0.23 versus 1.9 mg/dL is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N14 · Are the R02 open-label design and registration citation distinct from actual plans?

Required materials and conditions: Open-label pilot methods and official ACTRN history
Conditions for verification: Original records on Open-label pilot methods and official ACTRN history must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Open-label pilot methods and official ACTRN history is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N15 · Is the 2026 two-period/group design preserved?

Required materials and conditions: HesperidrinC groups/periods, drinks and crossover/allocation conditions
Conditions for verification: Original records on HesperidrinC groups/periods, drinks and crossover/allocation conditions must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on HesperidrinC groups/periods, drinks and crossover/allocation conditions is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N16 · Are 43 assigned, 40 analysed and 20 each for C/control distinguished?

Required materials and conditions: R03 allocation, analysis and single-agent drink contrast denominators
Conditions for verification: Original records on R03 allocation, analysis and single-agent drink contrast denominators must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on R03 allocation, analysis and single-agent drink contrast denominators is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N17 · Are time-specific R03 model mean±SE values preserved?

Required materials and conditions: C/control baseline, week 1 and week 2 model means/SE
Conditions for verification: Original records on C/control baseline, week 1 and week 2 model means/SE must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on C/control baseline, week 1 and week 2 model means/SE is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N18 · Are within-C P values distinguished from undetected between-drink differences?

Required materials and conditions: Within-group week 1 test and time-specific control contrasts
Conditions for verification: Original records on Within-group week 1 test and time-specific control contrasts must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Within-group week 1 test and time-specific control contrasts is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N19 · Are C+hesperidin and observational diet excluded from single-agent effects?

Required materials and conditions: Original contrasts for single-agent drinks versus combinations/natural diet
Conditions for verification: Original records on Original contrasts for single-agent drinks versus combinations/natural diet must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Original contrasts for single-agent drinks versus combinations/natural diet is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N20 · Are R03 official registration hierarchy and the paper-reported number distinguished?

Required materials and conditions: Official NCT04316390 change history and primary endpoints/time points
Conditions for verification: Original records on Official NCT04316390 change history and primary endpoints/time points must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Official NCT04316390 change history and primary endpoints/time points is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N21 · Is the pooled report of 13 RCTs kept distinct from a new primary trial?

Required materials and conditions: Juraschek review included/shared trials, extraction and heterogeneity
Conditions for verification: Original records on Juraschek review included/shared trials, extraction and heterogeneity must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Juraschek review included/shared trials, extraction and heterogeneity is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N22 · Are differences by disease, baseline status and medication retained?

Required materials and conditions: Directness for gout/non-gout, high urate, deficiency and medication
Conditions for verification: Original records on Directness for gout/non-gout, high urate, deficiency and medication must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Directness for gout/non-gout, high urate, deficiency and medication is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N23 · Are urate units, measurement and analysis sets distinguished?

Required materials and conditions: mg/dL, mmol/L, baseline/change values and measurement/adjustment
Conditions for verification: Original records on mg/dL, mmol/L, baseline/change values and measurement/adjustment must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on mg/dL, mmol/L, baseline/change values and measurement/adjustment is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N24 · What is the original impact of missingness, attrition and selective reporting?

Required materials and conditions: Group/stratum/period missingness, discontinuation, denominators and handling
Conditions for verification: Original records on Group/stratum/period missingness, discontinuation, denominators and handling must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Group/stratum/period missingness, discontinuation, denominators and handling is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N25 · Are first-onset gout, recurrence, cure and drug replacement kept separate?

Required materials and conditions: Direct comparison of serum urate and clinical gout events
Conditions for verification: Original records on Direct comparison of serum urate and clinical gout events must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Supplementary
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Direct comparison of serum urate and clinical gout events is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N26 · Are four company-involvement pathways and the three trials retained separately?

Required materials and conditions: Funding, in-kind/product support, employee authors and COI
Conditions for verification: Original records on Funding, in-kind/product support, employee authors and COI must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Funding, in-kind/product support, employee authors and COI is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N27 · Are 4 reports distinguished from unique trials and participants?

Required materials and conditions: Research families/shared samples of three original trials/comparisons and a review
Conditions for verification: Original records on Research families/shared samples of three original trials/comparisons and a review must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Research families/shared samples of three original trials/comparisons and a review is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N28 · Are harm collection, events and discontinuation known?

Required materials and conditions: Definition, collection and events/discontinuation for diarrhoea/gastrointestinal harms
Conditions for verification: Original records on Definition, collection and events/discontinuation for diarrhoea/gastrointestinal harms must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Supplementary
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Definition, collection and events/discontinuation for diarrhoea/gastrointestinal harms is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N29 · What are the safety denominators, exposure and comparators?

Required materials and conditions: Group/stratum/period actual treatment, safety sets and exposure/events
Conditions for verification: Original records on Group/stratum/period actual treatment, safety sets and exposure/events must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Supplementary
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Group/stratum/period actual treatment, safety sets and exposure/events is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N30 · What is known about kidney disease, stones, iron overload, coadministration and long-term harms?

Required materials and conditions: Vulnerable groups, alternative causes/medication and rare/long-term/independent harms
Conditions for verification: Original records on Vulnerable groups, alternative causes/medication and rare/long-term/independent harms must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Supplementary
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Vulnerable groups, alternative causes/medication and rare/long-term/independent harms is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N31 · Are historical HTML/PDF/abstract checks distinguished from current unread material?

Required materials and conditions: Original access record, stored summary and external abstracts/full text/registration/plans
Conditions for verification: Original records on Original access record, stored summary and external abstracts/full text/registration/plans must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Original access record, stored summary and external abstracts/full text/registration/plans is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N32 · Are Korean/English text, empty corrections and prior calculation records preserved?

Required materials and conditions: Complete originals, empty correction/subclaim records and prior calculation
Conditions for verification: Original records on Complete originals, empty correction/subclaim records and prior calculation must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Supplementary
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Complete originals, empty correction/subclaim records and prior calculation is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

N33 · Are original C54, axes and evidence date distinct from production?

Required materials and conditions: Original C54, caution, assessment axes and evidence date
Conditions for verification: Original records on Original C54, caution, assessment axes and evidence date must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Requirement and applicability: Required
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Why this condition is needed: Material on Original C54, caution, assessment axes and evidence date is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

What the statuses mean

Partly verified: Partial information from the stored summary is linked; detailed originals and content review remain incomplete.
Unverified: Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.
Review incomplete: Review of existing content remains incomplete.
Met: This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.
Not reported: Unreported within material actually read. Unread external material is not relabeled as unreported.
Inaccessible: This means actual access failure. External access was not attempted in this work, so this state was not assigned.
Not applicable: Used only with an application exception and reason based on the question scope.
Conflicting data: This requires actual comparison of materials; no new conflict judgment was made in this work.
Insufficient evidence for the conditions: This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade.

Change history

2026-10-22 · Public page/material version 1.0

Public-facing views and materials were prepared from the existing 33 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-09-07) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which urate question is addressed?

Current findings: The outcome is reduced serum urate in adults. Serum urate in mg/dL or mmol/L and gout attacks, first onset or recurrence are different questions.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original population, comparator and blood-test endpoint/time tables are needed. Gout prevention, cure or replacement of standard medication is not added.
Required materials and conditions: Direct comparison of oral single-ingredient C and serum urate in adults
Materials to obtain first: Original population, comparator and blood-test endpoint/time tables are needed. Gout prevention, cure or replacement of standard medication is not added.
Further research: Material needed: Original population, comparator and blood-test endpoint/time tables are needed. Gout prevention, cure or replacement of standard medication is not added. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Direct comparison of oral single-ingredient C and serum urate in adults must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Direct comparison of oral single-ingredient C and serum urate in adults is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N02 · Are tablets/capsules and C-added drinks distinguished?

Current findings: The formulation distinguishes tablets/capsules from the 2026 sugar-matched C-added drink. Naturally occurring food C, combinations and IV use are not automatically included.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original product, salt, added ingredients/sugars, manufacturing, excipients and single-agent conditions are needed. Formulation equivalence is not certified.
Required materials and conditions: Products/ingredients of ascorbic acid tablets/capsules and sugar-matched added-C drinks
Materials to obtain first: Original product, salt, added ingredients/sugars, manufacturing, excipients and single-agent conditions are needed. Formulation equivalence is not certified.
Further research: Material needed: Original product, salt, added ingredients/sugars, manufacturing, excipients and single-agent conditions are needed. Formulation equivalence is not certified. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Products/ingredients of ascorbic acid tablets/capsules and sugar-matched added-C drinks must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Products/ingredients of ascorbic acid tablets/capsules and sugar-matched added-C drinks is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N03 · Are 500 mg and nominal 600/measured 592±12 mg retained?

Current findings: Doses are main-trial 500 mg/day and the 2026 single-agent drink’s nominal 600 mg (measured 592±12 mg). Original units/± are retained without deriving conversions or recommendations.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original measurement, dispersion definition, ingredients, administration/adherence and trial-specific dose linkage are needed.
Required materials and conditions: Trial-specific dose, measured content, frequency and exposure
Materials to obtain first: Original measurement, dispersion definition, ingredients, administration/adherence and trial-specific dose linkage are needed.
Further research: Material needed: Original measurement, dispersion definition, ingredients, administration/adherence and trial-specific dose linkage are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Trial-specific dose, measured content, frequency and exposure must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Trial-specific dose, measured content, frequency and exposure is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N04 · Are 2 months, 8 weeks and 2 weeks retained separately?

Current findings: The duration distinguishes 2 months and 8 weeks from the 2026 trial’s 2 weeks. R01 bibliography records 184 participants over 2 months. Results are not relabeled as one duration.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Each report’s original schedule, actual dosing, post-stopping course and period/time linkage are needed.
Required materials and conditions: Original-trial exposure, measurement and follow-up end points
Materials to obtain first: Each report’s original schedule, actual dosing, post-stopping course and period/time linkage are needed.
Further research: Material needed: Each report’s original schedule, actual dosing, post-stopping course and period/time linkage are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Original-trial exposure, measurement and follow-up end points must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Original-trial exposure, measurement and follow-up end points is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N05 · Are non-gout, healthy high-urate and established-gout populations distinguished?

Current findings: The population separates adults without gout or healthy high-urate adults from established gout. The existing counterview retains differences in baseline urate, deficiency, medication and applicability to gout.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original diagnosis, baseline tests, medication/deficiency, eligibility/exclusions and group tables are needed. A pooled mean is not used as every population’s value.
Required materials and conditions: Population-specific baseline urate, diagnosis, deficiency and urate medication
Materials to obtain first: Original diagnosis, baseline tests, medication/deficiency, eligibility/exclusions and group tables are needed. A pooled mean is not used as every population’s value.
Further research: Material needed: Original diagnosis, baseline tests, medication/deficiency, eligibility/exclusions and group tables are needed. A pooled mean is not used as every population’s value. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Population-specific baseline urate, diagnosis, deficiency and urate medication must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Population-specific baseline urate, diagnosis, deficiency and urate medication is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N06 · Are placebo, drinks and allopurinol retained as different contrasts?

Current findings: The comparator separates placebo/sugar-matched drinks from direct allopurinol initiation or titration comparisons. An active-drug contrast is not relabeled as a placebo test of 0 effect.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original report/stratum-specific group conditions, drug initiation/titration, matched drinks and common care are needed.
Required materials and conditions: R01 placebo, R02 active-drug and R03 sugar-matched drink conditions
Materials to obtain first: Original report/stratum-specific group conditions, drug initiation/titration, matched drinks and common care are needed.
Further research: Material needed: Original report/stratum-specific group conditions, drug initiation/titration, matched drinks and common care are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on R01 placebo, R02 active-drug and R03 sugar-matched drink conditions must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on R01 placebo, R02 active-drug and R03 sugar-matched drink conditions is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N07 · Can diet, urate medication, coadministration and adherence be separated?

Current findings: The account retains applicability differences involving baseline urate medication, deficiency and sugary drinks. Detailed actual group-specific diet, medication and adherence remain unverified here.
Verification status: Unverified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original maintained/changed medication, diet, common care, adherence and discontinuation records are needed. An isolated C effect is not established.
Required materials and conditions: Baseline medication, treatment changes, diet/drinks and actual exposure
Materials to obtain first: Original maintained/changed medication, diet, common care, adherence and discontinuation records are needed. An isolated C effect is not established.
Further research: Material needed: Original maintained/changed medication, diet, common care, adherence and discontinuation records are needed. An isolated C effect is not established. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Baseline medication, treatment changes, diet/drinks and actual exposure must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Baseline medication, treatment changes, diet/drinks and actual exposure is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N08 · What are the R01 sample of 184 and group analysis denominators?

Current findings: R01 records 184 participants; group allocation and final analysis sample sizes remain unverified. Group counts, completers and attrition are not newly created.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original group flow, analysis/completion, missing endpoints and exclusion/missingness rules are needed.
Required materials and conditions: Huang trial allocation, analysis, completion and urate denominators
Materials to obtain first: Original group flow, analysis/completion, missing endpoints and exclusion/missingness rules are needed.
Further research: Material needed: Original group flow, analysis/completion, missing endpoints and exclusion/missingness rules are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Huang trial allocation, analysis, completion and urate denominators must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Huang trial allocation, analysis, completion and urate denominators is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N09 · What are R01 group-specific changes and CIs?

Current findings: The original result is C change −0.5 mg/dL (95% CI −0.6, −0.3), placebo +0.09 (−0.05, 0.2), between-group P<.0001. Group-change CIs are not transferred into a between-group difference CI.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original change/variance, groups/time points, denominators and adjustment/test tables are needed.
Required materials and conditions: Separate C/placebo change intervals and the between-group test
Materials to obtain first: Original change/variance, groups/time points, denominators and adjustment/test tables are needed.
Further research: Material needed: Original change/variance, groups/time points, denominators and adjustment/test tables are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Separate C/placebo change intervals and the between-group test must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Separate C/placebo change intervals and the between-group test is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N10 · Is the existing −0.59 calculation distinguished from its missing CI?

Current findings: The stored change difference −0.59 mg/dL is a calculation without its own 95% CI. It is not a new calculation or certification of an adjusted/precise effect in this work.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original between-group estimates, variance, CIs and model are needed. Group-specific CIs are not reused or reverse-calculated.
Required materials and conditions: Historical simple change difference and original between-group estimate/CI
Materials to obtain first: Original between-group estimates, variance, CIs and model are needed. Group-specific CIs are not reused or reverse-calculated.
Further research: Material needed: Original between-group estimates, variance, CIs and model are needed. Group-specific CIs are not reused or reverse-calculated. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Historical simple change difference and original between-group estimate/CI must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Historical simple change difference and original between-group estimate/CI is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N11 · Are R01 allocation, blinding and prior urate hierarchy known?

Current findings: R01 is a double-blind placebo RCT, but prior registration/SAP remain unverified. A design label does not certify every method or prespecification.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original methods, registration, plans and all endpoints/time points are needed. No formal RoB2/GRADE is produced.
Required materials and conditions: Sequence, concealment, blinding, registration/SAP and primary endpoint
Materials to obtain first: Original methods, registration, plans and all endpoints/time points are needed. No formal RoB2/GRADE is produced.
Further research: Material needed: Original methods, registration, plans and all endpoints/time points are needed. No formal RoB2/GRADE is produced. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Sequence, concealment, blinding, registration/SAP and primary endpoint must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Sequence, concealment, blinding, registration/SAP and primary endpoint is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N12 · Are the two R02 allopurinol strata kept distinct from treatment arms?

Current findings: R02 records 40 participants: 20 existing allopurinol users and 20 nonusers, with allocation within each stratum. These 20/20 are not relabeled as C-arm/active-control counts.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Stratum-specific drug initiation/titration, group allocation/analysis, baseline urate and flow tables are needed. Participants are not summed.
Required materials and conditions: Allocation/denominators within strata of 20 prior users and 20 nonusers
Materials to obtain first: Stratum-specific drug initiation/titration, group allocation/analysis, baseline urate and flow tables are needed. Participants are not summed.
Further research: Material needed: Stratum-specific drug initiation/titration, group allocation/analysis, baseline urate and flow tables are needed. Participants are not summed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Allocation/denominators within strata of 20 prior users and 20 nonusers must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Allocation/denominators within strata of 20 prior users and 20 nonusers is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N13 · What are the urate reductions in the R02 active comparison?

Current findings: R02 records reductions of 0.23 versus 1.9 mg/dL, P<.001, with the exact adjusted between-group CI unverified. The comparison shows a smaller response than allopurinol, not no C effect versus placebo.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original stratum/group, variance, model, CI and time/denominator result tables are needed. No new difference, 0 effect or flare-prevention estimate is created.
Required materials and conditions: Contrast, P value and adjusted CI for reductions of 0.23 versus 1.9 mg/dL
Materials to obtain first: Original stratum/group, variance, model, CI and time/denominator result tables are needed. No new difference, 0 effect or flare-prevention estimate is created.
Further research: Material needed: Original stratum/group, variance, model, CI and time/denominator result tables are needed. No new difference, 0 effect or flare-prevention estimate is created. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Contrast, P value and adjusted CI for reductions of 0.23 versus 1.9 mg/dL must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Contrast, P value and adjusted CI for reductions of 0.23 versus 1.9 mg/dL is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N14 · Are the R02 open-label design and registration citation distinct from actual plans?

Current findings: The design is an open-label randomized pilot with an active comparison. ACTRN12610000545066 is reported in the paper; official registration details remain unverified.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original methods, within-stratum allocation, registration/changes and protocol/SAP are needed. A registration identifier does not establish prespecification or reading.
Required materials and conditions: Open-label pilot methods and official ACTRN history
Materials to obtain first: Original methods, within-stratum allocation, registration/changes and protocol/SAP are needed. A registration identifier does not establish prespecification or reading.
Further research: Material needed: Original methods, within-stratum allocation, registration/changes and protocol/SAP are needed. A registration identifier does not establish prespecification or reading. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Open-label pilot methods and official ACTRN history must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Open-label pilot methods and official ACTRN history is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N15 · Is the 2026 two-period/group design preserved?

Current findings: R03 uses randomized drink comparisons with two study groups and two periods; not everyone received all four drinks. It is not relabeled as a universal 4-drink crossover.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original allocation/sequence, periods, drink conditions, washout, assessments/denominators and plans are needed.
Required materials and conditions: HesperidrinC groups/periods, drinks and crossover/allocation conditions
Materials to obtain first: Original allocation/sequence, periods, drink conditions, washout, assessments/denominators and plans are needed.
Further research: Material needed: Original allocation/sequence, periods, drink conditions, washout, assessments/denominators and plans are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on HesperidrinC groups/periods, drinks and crossover/allocation conditions must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on HesperidrinC groups/periods, drinks and crossover/allocation conditions is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N16 · Are 43 assigned, 40 analysed and 20 each for C/control distinguished?

Current findings: R03 records 43 assigned→40 analysed; 20 each for C and control drinks. Additional combination drinks, periods or people are not added and attrition is not calculated.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original group/period flow, endpoint denominators, missingness/exclusions and same-participant linkage are needed.
Required materials and conditions: R03 allocation, analysis and single-agent drink contrast denominators
Materials to obtain first: Original group/period flow, endpoint denominators, missingness/exclusions and same-participant linkage are needed.
Further research: Material needed: Original group/period flow, endpoint denominators, missingness/exclusions and same-participant linkage are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on R03 allocation, analysis and single-agent drink contrast denominators must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on R03 allocation, analysis and single-agent drink contrast denominators is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N17 · Are time-specific R03 model mean±SE values preserved?

Current findings: R03 records C 6.02±.20→5.54±.20 (week 1)→5.71±.20 (week 2); control 5.86±.20→5.76±.20→5.86±.20, as model mean±SE.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original units, model, adjustment, time/group, denominators and all contrasts are needed. SE is not relabeled as SD/CI and differences are not calculated.
Required materials and conditions: C/control baseline, week 1 and week 2 model means/SE
Materials to obtain first: Original units, model, adjustment, time/group, denominators and all contrasts are needed. SE is not relabeled as SD/CI and differences are not calculated.
Further research: Material needed: Original units, model, adjustment, time/group, denominators and all contrasts are needed. SE is not relabeled as SD/CI and differences are not calculated. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on C/control baseline, week 1 and week 2 model means/SE must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on C/control baseline, week 1 and week 2 model means/SE is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N18 · Are within-C P values distinguished from undetected between-drink differences?

Current findings: R03 retains within-C week 1 P<.01 alongside no detected time-specific between-group difference in the original account. It is not counted as positive between-group replication equivalent to the early RCT.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original between-group estimates/CIs, multiplicity, model and all time points are needed. Within-group significance is not converted into a placebo effect, equivalence or precise null effect.
Required materials and conditions: Within-group week 1 test and time-specific control contrasts
Materials to obtain first: Original between-group estimates/CIs, multiplicity, model and all time points are needed. Within-group significance is not converted into a placebo effect, equivalence or precise null effect.
Further research: Material needed: Original between-group estimates/CIs, multiplicity, model and all time points are needed. Within-group significance is not converted into a placebo effect, equivalence or precise null effect. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Within-group week 1 test and time-specific control contrasts must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Within-group week 1 test and time-specific control contrasts is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N19 · Are C+hesperidin and observational diet excluded from single-agent effects?

Current findings: The existing explanation excludes C+hesperidin and observational diet from single-agent confirmation. A combination in the paper title is not copied into an isolated effect.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original drink ingredients, allocation/periods, single-agent contrasts and distinction from combination/observational material are needed.
Required materials and conditions: Original contrasts for single-agent drinks versus combinations/natural diet
Materials to obtain first: Original drink ingredients, allocation/periods, single-agent contrasts and distinction from combination/observational material are needed.
Further research: Material needed: Original drink ingredients, allocation/periods, single-agent contrasts and distinction from combination/observational material are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Original contrasts for single-agent drinks versus combinations/natural diet must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Original contrasts for single-agent drinks versus combinations/natural diet is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N20 · Are R03 official registration hierarchy and the paper-reported number distinguished?

Current findings: The registration/citation record retains the paper-reported NCT04316390 identifier, while official history, primary hierarchy and time-point correspondence remain unverified.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original registration, changes, plans and analysis tables are needed. Current registration reading, compliance or prespecification is not certified.
Required materials and conditions: Official NCT04316390 change history and primary endpoints/time points
Materials to obtain first: Original registration, changes, plans and analysis tables are needed. Current registration reading, compliance or prespecification is not certified.
Further research: Material needed: Original registration, changes, plans and analysis tables are needed. Current registration reading, compliance or prespecification is not certified. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Official NCT04316390 change history and primary endpoints/time points must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Official NCT04316390 change history and primary endpoints/time points is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N21 · Is the pooled report of 13 RCTs kept distinct from a new primary trial?

Current findings: Bibliography-only R04 retains an average −0.35 mg/dL across 13 RCTs with substantial heterogeneity. Included-trial counts come from the original summary and are not new certification of unique trials or independent replication.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original inclusion/extraction tables, model, CIs, denominators and shared-trial/report links are needed. Review and primary-trial participants are not summed.
Required materials and conditions: Juraschek review included/shared trials, extraction and heterogeneity
Materials to obtain first: Original inclusion/extraction tables, model, CIs, denominators and shared-trial/report links are needed. Review and primary-trial participants are not summed.
Further research: Material needed: Original inclusion/extraction tables, model, CIs, denominators and shared-trial/report links are needed. Review and primary-trial participants are not summed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Juraschek review included/shared trials, extraction and heterogeneity must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Juraschek review included/shared trials, extraction and heterogeneity is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N22 · Are differences by disease, baseline status and medication retained?

Current findings: The original rationale retains mixed gout/high-urate results, while the counterview retains baseline and medication applicability limits. Findings are not simply merged as identical replication of one question.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original disease/baseline, formulation, duration, medication-specific effects/denominators and prespecified subgroups/interactions are needed.
Required materials and conditions: Directness for gout/non-gout, high urate, deficiency and medication
Materials to obtain first: Original disease/baseline, formulation, duration, medication-specific effects/denominators and prespecified subgroups/interactions are needed.
Further research: Material needed: Original disease/baseline, formulation, duration, medication-specific effects/denominators and prespecified subgroups/interactions are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Directness for gout/non-gout, high urate, deficiency and medication must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Directness for gout/non-gout, high urate, deficiency and medication is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N23 · Are urate units, measurement and analysis sets distinguished?

Current findings: The primary endpoint is serum urate in mg/dL or mmol/L. Original units are not converted and serum concentrations are not relabeled as flare outcomes.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original assay, units, blood sampling/time points, baseline adjustment, variance and estimand are needed.
Required materials and conditions: mg/dL, mmol/L, baseline/change values and measurement/adjustment
Materials to obtain first: Original assay, units, blood sampling/time points, baseline adjustment, variance and estimand are needed.
Further research: Material needed: Original assay, units, blood sampling/time points, baseline adjustment, variance and estimand are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on mg/dL, mmol/L, baseline/change values and measurement/adjustment must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on mg/dL, mmol/L, baseline/change values and measurement/adjustment is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N24 · What is the original impact of missingness, attrition and selective reporting?

Current findings: R01 unverified final group sample sizes, R02 within-stratum allocation and R03 allocation/analysis records are distinguished. Detailed missingness/exclusion rules remain unverified here.
Verification status: Unverified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Flow, attrition/exclusions, missing-data handling, all planned time points and sensitivity material are needed.
Required materials and conditions: Group/stratum/period missingness, discontinuation, denominators and handling
Materials to obtain first: Flow, attrition/exclusions, missing-data handling, all planned time points and sensitivity material are needed.
Further research: Material needed: Flow, attrition/exclusions, missing-data handling, all planned time points and sensitivity material are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Group/stratum/period missingness, discontinuation, denominators and handling must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Group/stratum/period missingness, discontinuation, denominators and handling is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N25 · Are first-onset gout, recurrence, cure and drug replacement kept separate?

Current findings: The existing explanation treats clinical gout as a separate question. Urate reduction or active-drug comparisons are not proof of first onset, recurrence, cure or drug replacement.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Direct tests of attacks, first onset, recurrence or drug replacement are separately needed. Other verdicts/research are not newly accessed here.
Required materials and conditions: Direct comparison of serum urate and clinical gout events
Materials to obtain first: Direct tests of attacks, first onset, recurrence or drug replacement are separately needed. Other verdicts/research are not newly accessed here.
Further research: Material needed: Direct tests of attacks, first onset, recurrence or drug replacement are separately needed. Other verdicts/research are not newly accessed here. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Direct comparison of serum urate and clinical gout events must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Direct comparison of serum urate and clinical gout events is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N26 · Are four company-involvement pathways and the three trials retained separately?

Current findings: R01 funding/manufacturer involvement is unverified; R02 records HRC New Zealand support with product/employee details unverified; R03 retains no external grant plus Döhler/Eckes-Granini/Ferrer in-kind support/I1. No grant is not relabeled as no company involvement.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original funding, in-kind/products, affiliations, COI and report-specific linkage are needed. Overall I2 and specific R03 I1 records are not replaced or rescored.
Required materials and conditions: Funding, in-kind/product support, employee authors and COI
Materials to obtain first: Original funding, in-kind/products, affiliations, COI and report-specific linkage are needed. Overall I2 and specific R03 I1 records are not replaced or rescored.
Further research: Material needed: Original funding, in-kind/products, affiliations, COI and report-specific linkage are needed. Overall I2 and specific R03 I1 records are not replaced or rescored. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Funding, in-kind/product support, employee authors and COI must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Funding, in-kind/product support, employee authors and COI is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N27 · Are 4 reports distinguished from unique trials and participants?

Current findings: The 3 trial summaries and 4 citations represent primary-material/review units. Original I2/R0 records are retained; independent replication or final unique trial/participant totals are not certified here.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Registration, institutions/timing, teams, products and included/additional-report/same-sample links are needed. Final totals are null.
Required materials and conditions: Research families/shared samples of three original trials/comparisons and a review
Materials to obtain first: Registration, institutions/timing, teams, products and included/additional-report/same-sample links are needed. Final totals are null.
Further research: Material needed: Registration, institutions/timing, teams, products and included/additional-report/same-sample links are needed. Final totals are null. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Research families/shared samples of three original trials/comparisons and a review must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Research families/shared samples of three original trials/comparisons and a review is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N28 · Are harm collection, events and discontinuation known?

Current findings: The original safety account retains high-dose gastrointestinal caution and limited event counts. Actual events, collection and causality are not newly established.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Original harm methods, severity, events/discontinuation, missingness and comparator records are needed.
Required materials and conditions: Definition, collection and events/discontinuation for diarrhoea/gastrointestinal harms
Materials to obtain first: Original harm methods, severity, events/discontinuation, missingness and comparator records are needed.
Further research: Material needed: Original harm methods, severity, events/discontinuation, missingness and comparator records are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Definition, collection and events/discontinuation for diarrhoea/gastrointestinal harms must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Definition, collection and events/discontinuation for diarrhoea/gastrointestinal harms is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N29 · What are the safety denominators, exposure and comparators?

Current findings: The 184, 40 and 43 assigned/40 analysed do not certify safety denominators. Different periods, medication or drinks are not combined as identical harm exposure.
Verification status: Unverified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Group-specific safety denominators, exposure/discontinuation, events and comparator/stratum/period linkage are needed. Incidence and totals are not calculated.
Required materials and conditions: Group/stratum/period actual treatment, safety sets and exposure/events
Materials to obtain first: Group-specific safety denominators, exposure/discontinuation, events and comparator/stratum/period linkage are needed. Incidence and totals are not calculated.
Further research: Material needed: Group-specific safety denominators, exposure/discontinuation, events and comparator/stratum/period linkage are needed. Incidence and totals are not calculated. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Group/stratum/period actual treatment, safety sets and exposure/events must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Group/stratum/period actual treatment, safety sets and exposure/events is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N30 · What is known about kidney disease, stones, iron overload, coadministration and long-term harms?

Current findings: The product account’s caution for stone predisposition, kidney disease and iron overload is retained. Urate results are not converted into certification of kidney/stone or long-term safety.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: Vulnerable populations, coadministration, event timing/alternative causes, independent reports, longer exposure and denominators are needed. No new harm search or judgment is performed.
Required materials and conditions: Vulnerable groups, alternative causes/medication and rare/long-term/independent harms
Materials to obtain first: Vulnerable populations, coadministration, event timing/alternative causes, independent reports, longer exposure and denominators are needed. No new harm search or judgment is performed.
Further research: Material needed: Vulnerable populations, coadministration, event timing/alternative causes, independent reports, longer exposure and denominators are needed. No new harm search or judgment is performed. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Vulnerable groups, alternative causes/medication and rare/long-term/independent harms must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Vulnerable groups, alternative causes/medication and rare/long-term/independent harms is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N31 · Are historical HTML/PDF/abstract checks distinguished from current unread material?

Current findings: Citations retain historical abstract/institutional bibliography checks and 2026 HTML/tables/methods/PDF-text checks with a PDF-screenshot cache failure. These are historical records, not current external reading or access testing.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: External material remains unread now. A past cache failure is not converted into current paper inaccessibility, and past checks are not promoted into newly completed QA.
Required materials and conditions: Original access record, stored summary and external abstracts/full text/registration/plans
Materials to obtain first: External material remains unread now. A past cache failure is not converted into current paper inaccessibility, and past checks are not promoted into newly completed QA.
Further research: Material needed: External material remains unread now. A past cache failure is not converted into current paper inaccessibility, and past checks are not promoted into newly completed QA. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Original access record, stored summary and external abstracts/full text/registration/plans must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Original access record, stored summary and external abstracts/full text/registration/plans is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N32 · Are Korean/English text, empty corrections and prior calculation records preserved?

Current findings: Korean/English text, empty correction/subclaim arrays and the original −0.59 calculation label are retained. No new calculation, correction or completed English clinical review is created.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: After content review, new material, corrections or verdict changes are recorded as separate events.
Required materials and conditions: Complete originals, empty correction/subclaim records and prior calculation
Materials to obtain first: After content review, new material, corrections or verdict changes are recorded as separate events.
Further research: Material needed: After content review, new material, corrections or verdict changes are recorded as separate events. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Complete originals, empty correction/subclaim records and prior calculation must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Complete originals, empty correction/subclaim records and prior calculation is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04

N33 · Are original C54, axes and evidence date distinct from production?

Current findings: C/54/caution, original assessment axes and the existing evidence date 2026-09-07 are retained. Original independence/pooled-signal wording is historical, not a new grade or certification in this work.
Verification status: Partly verified
Materials actually read: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread
Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
Reason for missing information: New material, condition revisions and verdict changes are separate events after content review. The original date is not used as a current search or external reading date.
Required materials and conditions: Original C54, caution, assessment axes and evidence date
Materials to obtain first: New material, condition revisions and verdict changes are separate events after content review. The original date is not used as a current search or external reading date.
Further research: Material needed: New material, condition revisions and verdict changes are separate events after content review. The original date is not used as a current search or external reading date. This records needed materials; no new research was executed.
Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work.
Conditions for verification: Original records on Original C54, caution, assessment axes and evidence date must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews.
Why this condition is needed: Material on Original C54, caution, assessment axes and evidence date is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms.
Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created.
Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.

Related sources R01 R02 R03 R04